Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | COL1A1 | P02452 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990162 | 0.82 | KDM4E (0.72) | KDM4EGLARCE1CYP1A2CYP3A4 | |
| SCHEMBL990879 | 0.77 | KDM4E (0.64) | KDM4EGLARCE1CYP1A2CYP3A4 | |
| Acetic Acid SCHEMBL2478031 | 0.77 | KDM4E (0.67) | KDM4EGLARCE1CYP1A2CYP3A4 | |
| SCHEMBL12200072 | 0.75 | KDM4E (0.58) | KDM4EGLARCE1CYP1A2CYP3A4 | |
| SCHEMBL3654274 | 0.75 | KDM4E (0.61) | KDM4EGLARCE1CYP1A2CYP3A4 | |
| SCHEMBL4098416 | 0.71 | KDM4E (0.73) | KDM4EGLARCE1CYP1A2CYP3A4 | |
| SCHEMBL28494818 | 0.71 | KDM4E (0.49) | KDM4EGLARCE1CYP1A2CYP3A4 | |
| SCHEMBL948574 | 0.69 | MTNR1B (0.39) | MEN1KMT2AROCK2ROCK1HCRTR1 | |
| SCHEMBL1363818 | 0.69 | KDM4E (0.37) | KDM4EGLARCE1DRD2DRD3 | |
| SCHEMBL2958134 | 0.67 | KDM4E (0.63) | KDM4EGLARCE1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451281-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| WO-2011005636-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005636-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | KDM4E 3242/4885GLA 4779/4885RCE1 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.